Puma Biotechnology (NASDAQ:PBYI) presented its Q1 2025 earnings call on May 8, 2025, highlighting the commercial performance of its flagship product NERLYNX. Despite missing analyst expectations with revenue of $46 million against a forecasted $47.5 million, the company’s stock rose 4.23% in after-hours trading to $3.20, suggesting investors found positive elements in the presentation.
The $151 million market cap biotech company continues to focus on expanding NERLYNX’s global footprint while optimizing patient dosing strategies to improve adherence. The presentation offered insights into both the challenges and opportunities facing Puma (OTC:PMMAF) as it navigates competitive pressures in the oncology treatment landscape.
Quarterly Performance Highlights
Puma reported NERLYNX net revenue of $43.1 million for Q1 2025, representing a 7% increase compared to Q1 2024 ($40.3 million). However, this figure reflects a significant 21% decrease from Q4 2024 ($54.4 million). The quarterly performance was notably impacted by inventory changes, with a negative $4.7 million inventory adjustment in Q1 2025.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.